Medicare Enrolled

Dr. Ildiko Lingvay, MD

Endocrinology · Dallas, TX
Practice pattern: Mixed Practice — Diverse clinical practice across multiple procedure types
5323 HARRY HINES BLVD, Dallas, TX 75390
2146452868
Registered in NPPES since 2006
NPI: 1447216916 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Lingvay from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Lingvay? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Lingvay

Dr. Ildiko Lingvay is an endocrinology specialist in Dallas, TX, with 20 years of NPI registration. Based on federal Medicare data, Dr. Lingvay performed 11 Medicare services in 2023. These records do not provide a deduplicated patient total.

Between the years covered by Open Payments, Dr. Lingvay received a total of $677,637 from 27 pharmaceutical and/or device companies across 499 payment records. A record can group multiple payments. These transfers are publicly reported through CMS Open Payments. Disclosure alone does not establish their effect on care. A reliable breakdown by payment category is not available in this snapshot. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Lingvay is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 20 years of NPI registration ▲ 11 Medicare services $677,637 industry payments

Medicare Practice Summary — 2023

Medicare Utilization ↗
11
Medicare services
Not available
Unique patients (not deduplicated)
$102
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

Procedure Volume Avg. paid Avg. submitted
Initial hospital admission, moderate complexity
Initial hospital inpatient or observation care for a new patient involving moderate-level medical decision making, with at least 55 minutes total time on the date of the encounter.
11 $102 $445
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. These counts do not measure clinical quality or years of experience.

Industry Payment Transparency

Open Payments through 2024 ↗
$677,637
Total received (2018-2024)
Avg $96,805/year across 7 years
Top 3% in TX for endocrinology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
27
Companies
499
Payment records
Payments are publicly reported; disclosure does not establish legality · Not evidence of wrongdoing · How to interpret →

Payment categories are unavailable while the source breakdown is being rebuilt. Company and year totals do not identify how much belongs to each category.

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$129,391
2023
$82,711
2022
$139,767
2021
$32,752
2020
$38,101
2019
$114,983
2018
$139,932

Payments by company (2024)

Novo Nordisk AS
$36,981
Boehringer Ingelheim Pharmaceuticals, Inc.
$16,269
Regeneron Pharmaceuticals, Inc.
$14,659
Eli Lilly and Company
$13,244
Zealand Pharma A/S
$9,777
ABBVIE INC.
$8,825
AstraZeneca UK Limited
$7,250
Neurocrine Biosciences, Inc.
$6,000
AstraZeneca Pharmaceuticals LP
$5,525
Amgen Inc.
$5,410
PFIZER INC.
$4,000
Shionogi Inc
$1,390
Corcept Therapeutics
$59
Top 3 companies account for 52.5% of 2024 payments
All-time payments by company (2018-2024) ›
Novo Nordisk AS
$231,171
Eli Lilly and Company
$92,649
Novo Nordisk Inc
$52,028
AstraZeneca Pharmaceuticals LP
$46,451
SANOFI-AVENTIS U.S. LLC
$31,073
AstraZeneca UK Limited
$30,023
Boehringer Ingelheim International GmbH
$23,467
Medical Device Business Services, Inc.
$23,418
Boehringer Ingelheim Pharmaceuticals, Inc.
$22,594
Janssen Scientific Affairs, LLC
$17,989
Zealand Pharma A/S
$16,627
Regeneron Pharmaceuticals, Inc.
$14,659
Merck Sharp & Dohme LLC
$12,314
Lilly USA, LLC
$9,293
ABBVIE INC.
$8,825
Zealand Pharma US, Inc.
$7,898
Merck Sharp & Dohme Corporation
$6,878
Neurocrine Biosciences, Inc.
$6,000
Amgen Inc.
$5,410
PFIZER INC.
$4,575
Intercept Pharmaceuticals, Inc.
$3,850
Shionogi Inc
$3,462
MannKind Corporation
$3,000
Ethicon US, LLC
$1,960
Bayer HealthCare Pharmaceuticals Inc.
$1,880
GlaxoSmithKline, LLC.
$83
Corcept Therapeutics
$59
Top 3 companies account for 55.5% of all-time payments
Associated products mentioned in payments ›
AFREZZA · Dasiglucagon · Echelon Flex · Echelon; Endopath · FARXIGA · INVOKANA · JARDIANCE · Korlym · MOUNJARO · NO PRODUCT DISCUSSED · Non-Covered · Ozempic · SOLIQUA 100/33 · STEGLATRO · Saxenda · TOUJEO · TRADJENTA · TRULICITY · TZIELD · Tresiba · Victoza · Xultophy 100/3.6 · ZEGALOGUE
Should you be concerned? Industry payments are disclosed through CMS Open Payments. Disclosure alone does not establish their purpose, legality, or effect on care. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Looking for an endocrinology specialist in Dallas?
Compare endocrinologists in the Dallas area by procedure volume, costs, and industry payment transparency.
Browse endocrinologists nearby

Geographic Context

Endocrinologists in nearby ZIP areas
98
County median income
$74,149
Nearest hospital to ZIP centroid (approximate)
UT OF TEXAS SOUTHWESTERN UNIVERSITY HOSPITAL - WILLIAM P. CLEMENTS JR.
0.0 mi

Data Sources

Provider Registry NPPES NPPES snapshot; verify current record
Medicare Enrollment PECOS PECOS snapshot
Practice Data Medicare Util. Annual (CY lag)
Industry Payments Open Payments CY 2024
Disciplinary History — Not included N/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →

Summary

Dr. Lingvay is a mixed practice specialist, with 20 years of NPI registration.

This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →

Frequently Asked Questions

Is Dr. Lingvay experienced with initial hospital admission, moderate complexity?
Based on Medicare claims data, Dr. Lingvay performed 11 initial hospital admission, moderate complexity services. These records cover Medicare fee-for-service activity, including eligible younger beneficiaries; they do not measure total practice volume or clinical quality.
Does Dr. Lingvay receive payments from pharmaceutical companies?
Yes. Dr. Lingvay received a total of $677,637 from 27 companies across 499 payment records. A record can group multiple payments. These transfers are publicly disclosed through CMS Open Payments. Disclosure alone does not establish their legality or effect on care. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Lingvay's costs compare to other endocrinologists in Dallas?
Dr. Lingvay's average Medicare payment per service is $102. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Lingvay) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating the presence of registry, enrollment, activity or payment records, not verified experience or clinical quality. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Source publication dates and the snapshots loaded on this site can differ. Rebuilding a page does not refresh its source records. Check the Medicare reporting year and the payment interval shown above; consult the linked official sources for newer releases and current registry details. See our data freshness policy →
About this page

This page combines public CMS records with calculated summaries and explanatory procedure labels. These transformations are not verbatim federal records. Sources: NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Industry payment disclosure alone establishes neither wrongdoing nor legality. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →